Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.
The owner of a telemarketing company implicated in the largest component of a $1.2 billion Medicare fraud involving the supply of medically unnecessary orthotic braces pleaded guilty to criminal charges, the U.S. Department of Justice said.
Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.
Less than a month after filing for bankruptcy, Insys Therapeutics gained a reprieve from some lawsuits as well as a path forward for regulatory approval of an opioid overdose treatment.
Insys Therapeutics Inc. agreed to pay $225 million and an operating unit will plead guilty to fraud to settle probes into their payment of kickbacks to induce doctors to prescribe highly addictive opioids, the U.S. Department of Justice said.
The U.S. government filed a civil lawsuit accusing Rochester Drug-Cooperative Inc., a large opioid distributor, of failing to report thousands of suspicious orders for controlled substances as part of a years-long drive to bolster profit.
U.S. authorities said 24 defendants were charged in connection with one of the largest healthcare fraud schemes prosecuted by the federal government, involving telemedicine companies and resulting in more than $1.2 billion of losses.
Duke University will pay the U.S. government $112.5 million to settle claims related to scientific research misconduct, the Department of Justice said.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
Sanofi reached a civil settlement with the U.S. Securities and Exchange Commission fully resolving the SEC’s investigation into possible violations of the U.S. Foreign Corrupt Practices Act.
